| Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer (NCT07686640) | Shandong Cancer Hospital and Institute | 2026-08-15 |
| SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer (NCT07683221) | Shandong Cancer Hospital and Institute | 2026-07-15 |
| Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer (NCT07595107) | Shandong Cancer Hospital and Institute | 2026-06-01 |
| Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer (NCT07408505) | Shandong Cancer Hospital and Institute | 2026-06-01 |
| Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis (NCT07403370) | Shandong Cancer Hospital and Institute | 2026-01-18 |
| The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy (NCT07376174) | Shandong Cancer Hospital and Institute | 2026-01-10 |
| Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (NCT07333274) | Shandong Cancer Hospital and Institute | 2026-01-05 |
| A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment (NCT07669051) | Shandong Cancer Hospital and Institute | 2026-01-01 |
| SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma (NCT07274774) | Shandong Cancer Hospital and Institute | 2025-11-30 |
| Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer (NCT07173387) | Shandong Cancer Hospital and Institute | 2025-10-01 |
| Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes (NCT07187752) | Shandong Cancer Hospital and Institute | 2025-09-30 |
| Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study (NCT07173374) | Shandong Cancer Hospital and Institute | 2025-09-10 |
| Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer (NCT07600268) | Shandong Cancer Hospital and Institute | 2025-08-14 |
| Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer (NCT07093931) | Shandong Cancer Hospital and Institute | 2025-08-01 |
| Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial (NCT06850090) | Shandong Cancer Hospital and Institute | 2025-07-30 |
| BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases (NCT07062055) | Shandong Cancer Hospital and Institute | 2025-07-25 |
| Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC (NCT06841172) | Shandong Cancer Hospital and Institute | 2025-07-21 |
| SFRT and SCART in Radiotherapy for Bone Metastases With Soft Tissue (NCT06987370) | Shandong Cancer Hospital and Institute | 2025-06-01 |
| Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury (NCT06847555) | Shandong Cancer Hospital and Institute | 2025-05-25 |
| Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma (NCT06980259) | Shandong Cancer Hospital and Institute | 2025-05-20 |
| Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (NCT06802757) | Shandong Cancer Hospital and Institute | 2025-05-01 |
| Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT) (NCT07026422) | Shandong Cancer Hospital and Institute | 2025-04-30 |
| Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer (NCT06942416) | Shandong Cancer Hospital and Institute | 2025-02-28 |
| Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) (NCT06844422) | Shandong Cancer Hospital and Institute | 2025-02-08 |
| Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents (NCT06816771) | Shandong Cancer Hospital and Institute | 2025-02-01 |
| Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06714266) | Shandong Cancer Hospital and Institute | 2024-12-15 |
| A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. (NCT06649448) | Shandong Cancer Hospital and Institute | 2024-10-10 |
| Early Screening Cohort Study of Multiple Gastrointestinal Tumors (NCT07106424) | Shandong Cancer Hospital and Institute | 2024-09-10 |
| Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer. (NCT06778382) | Shandong Cancer Hospital and Institute | 2024-06-24 |
| Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma (NCT06532539) | Shandong Cancer Hospital and Institute | 2024-06-13 |
| WASPE Sleep Adjustment for Children Aged 0-4 Years Undergoing Radiation Therapy (NCT06443632) | Shandong Cancer Hospital and Institute | 2024-06-01 |
| A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer (NCT06398405) | Shandong Cancer Hospital and Institute | 2024-04-22 |
| First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC (NCT06370663) | Shandong Cancer Hospital and Institute | 2024-04-01 |
| Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases (NCT06356584) | Shandong Cancer Hospital and Institute | 2024-04-01 |
| Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer (NCT06261047) | Shandong Cancer Hospital and Institute | 2024-03-01 |
| Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer (NCT06246344) | Shandong Cancer Hospital and Institute | 2023-12-01 |
| Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer (NCT06050317) | Shandong Cancer Hospital and Institute | 2023-08-18 |
| Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia (NCT06924749) | Shandong Cancer Hospital and Institute | 2023-06-05 |
| A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma (NCT05933967) | Shandong Cancer Hospital and Institute | 2023-06-01 |
| Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients (NCT05758571) | Shandong Cancer Hospital and Institute | 2023-01-05 |
| Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC (NCT06241807) | Shandong Cancer Hospital and Institute | 2022-12-02 |
| CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer (NCT07316309) | Shandong Cancer Hospital and Institute | 2022-11-28 |
| Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma. (NCT05323890) | Shandong Cancer Hospital and Institute | 2022-04-20 |
| A Phase I Study of IBI325 in Patients With Advanced Solid Tumor (NCT05246995) | Shandong Cancer Hospital and Institute | 2022-03-23 |
| A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma (NCT05185531) | Shandong Cancer Hospital and Institute | 2022-03-01 |
| Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS Cohort (NCT05054777) | Shandong Cancer Hospital and Institute | 2021-10-01 |
| Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer (NCT05039983) | Shandong Cancer Hospital and Institute | 2021-08-20 |
| Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy (NCT04829708) | Shandong Cancer Hospital and Institute | 2021-04-26 |
| A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma (NCT05099848) | Shandong Cancer Hospital and Institute | 2021-03-17 |
| A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC (NCT04982549) | Shandong Cancer Hospital and Institute | 2021-01-21 |
| Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis (NCT04639271) | Shandong Cancer Hospital and Institute | 2021-01-01 |
| Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC (NCT04609540) | Shandong Cancer Hospital and Institute | 2021-01-01 |
| A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NCT04958993) | Shandong Cancer Hospital and Institute | 2020-11-12 |
| A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients (NCT04619563) | Shandong Cancer Hospital and Institute | 2020-11-04 |
| Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer (NCT04568941) | Shandong Cancer Hospital and Institute | 2020-11-01 |
| A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer (NCT04619537) | Shandong Cancer Hospital and Institute | 2020-10-08 |
| SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC (NCT04562337) | Shandong Cancer Hospital and Institute | 2020-10-01 |
| A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma (NCT04552977) | Shandong Cancer Hospital and Institute | 2020-09-01 |
| A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment (NCT04560244) | Shandong Cancer Hospital and Institute | 2020-09-01 |
| Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) (NCT04676997) | Shandong Cancer Hospital and Institute | 2020-05-20 |
| Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer (NCT04246502) | Shandong Cancer Hospital and Institute | 2020-01-01 |
| Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer (NCT04143906) | Shandong Cancer Hospital and Institute | 2019-10-25 |
| Metabolomics Explores Biomarkers for Metastatic Breast Cancer (NCT04302415) | Shandong Cancer Hospital and Institute | 2019-10-01 |
| Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib (NCT04004975) | Shandong Cancer Hospital and Institute | 2019-06-25 |
| Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (NCT03884192) | Shandong Cancer Hospital and Institute | 2018-12-12 |
| Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients (NCT03672136) | Shandong Cancer Hospital and Institute | 2018-11-01 |
| Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors (NCT04110223) | Shandong Cancer Hospital and Institute | 2018-10-08 |
| Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy (NCT03684863) | Shandong Cancer Hospital and Institute | 2018-10-01 |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC (NCT03557411) | Shandong Cancer Hospital and Institute | 2018-07-09 |
| Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique (NCT03541278) | Shandong Cancer Hospital and Institute | 2018-07-01 |
| Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients (NCT03489616) | Shandong Cancer Hospital and Institute | 2018-01-15 |
| The Multi-center Validation Study of Internal Mammary Lymph Biopsy With Modified Injection Technique in Breast Cancer Patients (NCT03024463) | Shandong Cancer Hospital and Institute | 2017-08-01 |
| Minimally Invasive Biopsy Predicting Breast pCR After NAC for Breast Cancer (NCT03789851) | Shandong Cancer Hospital and Institute | 2017-06-01 |
| Detection of CSF Next Generation Sequencing in the Application of Brain Metastases From Lung Adenocarcinoma or Meningeal Metastasis (NCT03029065) | Shandong Cancer Hospital and Institute | 2017-01-01 |
| Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases (NCT03414944) | Shandong Cancer Hospital and Institute | 2016-12-02 |
| Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M (NCT02972333) | Shandong Cancer Hospital and Institute | 2016-12-01 |
| Shandong Cancer Hospital Affiliated to Shandong University (NCT02958033) | Shandong Cancer Hospital and Institute | 2016-11-01 |
| Temperature and Injury in Radiotherapy Radiation Skin Injury (NCT04047823) | Shandong Cancer Hospital and Institute | 2016-10-02 |
| The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. (NCT03384511) | Shandong Cancer Hospital and Institute | 2016-09-30 |
| Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients (NCT02793791) | Shandong Cancer Hospital and Institute | 2016-09-01 |
| A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC (NCT02721550) | Shandong Cancer Hospital and Institute | 2016-08-01 |
| A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC (NCT02721576) | Shandong Cancer Hospital and Institute | 2016-07-05 |
| A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC (NCT02721563) | Shandong Cancer Hospital and Institute | 2016-02-25 |
| Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer (NCT02544243) | Shandong Cancer Hospital and Institute | 2015-09-01 |
| Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT02790190) | Shandong Cancer Hospital and Institute | 2015-05-01 |
| Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy (NCT02577393) | Shandong Cancer Hospital and Institute | 2015-04-01 |
| A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma (NCT02409186) | Shandong Cancer Hospital and Institute | 2015-03-01 |
| Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy (NCT02580279) | Shandong Cancer Hospital and Institute | 2014-12-01 |
| Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer (NCT02195453) | Shandong Cancer Hospital and Institute | 2014-08-01 |
| Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer (NCT02191059) | Shandong Cancer Hospital and Institute | 2014-07-01 |
| Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive (NCT01668914) | Shandong Cancer Hospital and Institute | 2014-02-01 |
| A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma (NCT01939574) | Shandong Cancer Hospital and Institute | 2013-08-01 |
| Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node (NCT01796444) | Shandong Cancer Hospital and Institute | 2013-01-01 |
| TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma (NCT01605734) | Shandong Cancer Hospital and Institute | 2012-07-01 |
| Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma (NCT01556815) | Shandong Cancer Hospital and Institute | 2012-05-01 |
| Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative (NCT01642511) | Shandong Cancer Hospital and Institute | 2012-01-01 |
| Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis (NCT01481818) | Shandong Cancer Hospital and Institute | 2011-09-01 |
| Intraoperative Molecular Diagnosis of Sentinel Lymph Node In Breast Cancer Patients (NCT03937414) | Shandong Cancer Hospital and Institute | 2010-02-01 |
| IMRT/Pemetrexed/Cisplatin in Esophageal Cancer (NCT01630174) | Shandong Cancer Hospital and Institute | 2009-10-01 |
| Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma (NCT00815308) | Shandong Cancer Hospital and Institute | 2009-01-01 |